

OFFICIALLY LICENSED

BEST OF ASCO®

2021 ANNUAL MEETING

31st July & 1st August 2021

Malaysia

CPD Points by



In collaboration with



Malaysian
Oncological
Society

SCIENTIFIC AGENDA

MMA Event Code for Best of ASCO 2021, Malaysia

CPDE26363

A1-16 CPD Points Awarded

For more information on the CPD Points, visit our website.



<https://malaysia.bestofoncology.org/MMA-CPD.php>

Presented by



Scientific Programme

DAY 1 | 31ST JULY 2021 | SATURDAY

Time	Session Type	Speaker	Moderator/ Chair Person	Title of Presentation
11:00 - 12:00	MSD Immuno-Oncology MasterClass - Emerging Cancer Immunotherapy Biomarker: Microsatellite Instability (MSI) / Mismatch Repair (MMR)			
11:00 - 11:05	MSD Immuno Oncology MasterClass		Dr. Lee Bang Rom	Welcome and Opening Remarks.
11:05 - 11:20			Dr. Lee Bang Rom	Prognostic and Predictive Value of MMR Status Identification.
11:20 - 11:45			Dr. Ho Gwo Fuang	Value of dMMR / MSI-H Testing for CRC IO Treatment.
11:45 - 11:55			 Dr. Lee Bang Rom	Q&A Session.
11:55 - 12:00			Dr. Lee Bang Rom	Closing Remarks.
12:00	Welcome Address by Dr. Malwinder Singh Sandhu - Member, Organizing Committee			
12:05 - 13:50	Session 1 - Breast Cancer - Metastatic / Local / Regional / Adjuvant			
12:05 - 12:15	Session by Roche		Dr. Lim Chun Sen	IMpassion130 Final overall Analysis and the Clinical Utility of SP142 in mTNBC.
12:15 - 12:25	Presentation		Dr. Najihah Abu Bakar	Trastuzumab Plus Endocrine Therapy or Chemotherapy as first-line Treatment for Metastatic Breast Cancer with Hormone Receptor-Positive and HER2-positive: The Sysucc-002 Randomized Clinical Trial.
12:25 - 12:35	Presentation		Dr. Nahjatul Kursyah Abd Ghafar	Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study.
12:35 - 12:45	Presentation		Ms. Anne L. Loeser	Treatment-related side effects and views about dosage assessment to sustain quality of life: Results of an advocate-led survey of patients with metastatic breast cancer (MBC).
12:45 - 12:55	Presentation		Dr. Oleg Gluz	De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.
12:55 - 13:05	Presentation		Dr. Syafirin Ab Sani	Breast Cancer Index (BCI) and Prediction of Benefit from Extended Aromatase Inhibitor (AI) Therapy (tx) in HR+ Breast Cancer: NRG Oncology/NSABP B-42.
13:05 - 13:15	Presentation		Dr. Josephine Lopes Cardozo	Outcome of patients with an ultralow risk 70-gene signature in the MINDACT trial.
13:15 - 13:35	Session by Zuellig		Dr. Ang Soo Fan	Management of HR+ HER2- MBC: A Case Based Discussion.
13:35 - 13:50	Panel Discussion & Q&A Session			
Quick Quiz Question				
13:50 - 14:10	Exhibition Tour Break			

14:10 - 14:40**Session 2 - Head & Neck Cancer**

14:10 - 14:20 Presentation



Dr. Li Zhang

Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase III trial.

14:20 - 14:30 Presentation



Dr. Choong Swee Hsia

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Results from the phase 3 COSMIC-311 trial.

14:30 - 14:40 Presentation



Dr. Wong Yoke Fui

Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.

14:40 - 15:20**Session 3 - Lower Gastrointestinal Cancer**

14:40 - 14:50 Presentation



Dr. Richard Adams

Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial.

14:50 - 15:00 Presentation



Dr. Takayuki Yoshino

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).

15:00 - 15:10 Presentation



Dr. Sucharit Pongprakyun

Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer.

15:10 - 15:20 Presentation



Dr. Yasutoshi Kuboki

The TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer.

15:20 - 16:10**Session 4 - Upper Gastrointestinal Cancer**

15:20 - 15:30 Presentation



Dr. Ronan Joseph Kelly

Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): expanded efficacy and safety analyses from CheckMate 577.

15:30 - 15:40 Presentation



Dr. David Lee

Hepatic arterial infusion chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase 3 trial (The FOHAIC-1 study).

15:40 - 16:10 Session by BMS



Dr. Matthew Ng



Dr. Tho Lye Mun

Optimising first line therapy in metastatic gastroesophageal cancers.

Quick Quiz Question**16:10 - 16:30****Exhibition Tour Break**

16:30 - 17:10

Session 5 - Gynaecological Cancer

16:30 - 16:40 Presentation

Dr. Hafizah
Zaharah

Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890).

16:40 - 16:50 Presentation



Dr. Paolo Zola

Intensive versus minimalist follow-up in patients treated for endometrial cancer: A multicentric randomized controlled trial (The TOTEM study—NCT00916708).


16:50 - 17:00 Presentation



Dr. Lim Chun Sen

Maintenance vigil immunotherapy in newly diagnosed advanced ovarian cancer: Efficacy assessment of homologous recombination proficient (HRP) patients in the phase IIb VITAL trial.

17:00 - 17:10 Presentation

Dr. Natasha Mohd
Hashim

Mirvetuximab soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis.

17:10 - 18:30

Session 6 - Genitourinary Cancer

17:10 - 17:20 Presentation

Dr. Ngu Ming
Ruey

Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial.

17:20 - 17:30 Presentation



Dr. Adlinda Alip

A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.

17:30 - 17:40 Presentation

Dr. Robert J.
Motzer

Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC).

17:40 - 17:50 Presentation



Dr. Brian I. Rini

Final analysis of KEYNOTE-426: Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC).

17:50 - 18:00 Presentation

Dr. Bernadette
Szabados

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.

18:00 - 18:30 Session by BMS

Dr. Bernard
Escudier

Dr. Tho Lye Mun

Shifting paradigms in RCC with Immunotherapy.

18:30

Quiz Session 1

DAY 2 | 1ST AUGUST 2021 | SUNDAY

Time	Session Type	Speaker	Moderator/ Chair Person	Title of Presentation
10:55	Opening Remarks by Dr. Malwinder Singh Sandhu - Member, Organizing Committee			
11:00 - 12:50	Session 7 – Lung Cancer (NSCLC)			
11:00 - 11:20	Session with LIVE Q&A by Boehringer Ingelheim	 Dr. Ho Gwo Fuang	 Dr. Yap Beng Khiong	PeRsonalized apprOach in Lung AdenOcarciNoma with EGFR-TKI therapy (PROLONG).
11:20 - 11:30	Presentation	 Dr. Heather Wakelee		IMpower010: Primary results of a phase III global study of atezolizumab vs. best supportive care after adjuvant chemotherapy in resected Stage IB-IIIa non-small cell lung cancer (NSCLC).
11:30 - 11:40	Presentation	 Dr. Nisha Shariff		First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.
11:40 - 11:50	Presentation	 Dr. Shazril Imran Shaukat		Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150.
11:50 - 12:00	Presentation	 Dr. Vance Koi		Racial disparities in biomarker testing and clinical trial enrollment in non-small cell lung cancer (NSCLC).
12:00 - 12:10	Presentation	 Dr. Byoung Chul Cho		Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.
12:10 - 12:30	Session by Zuellig	 Dr. Liam Chong Kin		The Role of Anti-angiogenics in the Management of EGFR+ mNSCLC.
12:30 - 12:50	Panel Discussion & Q&A Session			
12:50 - 13:10	Session 8 – Lung Cancer (Small Cell)			
12:50 - 13:00	Presentation	 Dr. Hadi Abdul Jalil		Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538.
13:00 - 13:10	Presentation	 Dr. Lim Yueh Ni		A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma.
Quick Quiz Question				
13:10 - 13:45	Exhibition Tour Break			
13:45 - 14:25	Session 9 – Musculoskeletal Cancer			
13:45 - 13:55	Presentation	 Dr. Rizma Mohd Zaid		Treatment delays are associated with an unfavorable outcome in patients with localized Ewing sarcoma: A retrospective analysis of data from the GPOH Euro-E.W.I.N.G.99 trial.
13:55 - 14:05	Presentation	 Dr. Lim Yi Way		Eribulin and gemcitabine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A multicenter, single-arm, phase 2-trial.

14:05 - 14:15	Presentation		Dr. Teo Yin Keong	High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes:
14:15 - 14:25	Presentation		Dr. Audi Adawiah	SPEARHEAD-1: A phase 2 trial of afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.
14:25 - 14:55 Session 10 – CNS Cancer				
14:25 - 14:35	Presentation		Dr. Eng Jie Yi	Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas.
14:35 - 14:45	Presentation		Dr. Sébastien Perreault	Efficacy and safety of larotrectinib in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system tumors.
14:45 - 14:55	Presentation		Dr. Noor Zafifah Zakaria	Long-term results of the GEINO 140 TRIAL: randomizing patients to stop or to continue temozolomide until 12 cycles.
Quick Quiz Question				
15:00 - 15:40 Session 11 – Skin Cancer (Melanoma)				
15:00 - 15:10	Presentation		Dr. Evan J. Lipson	Relatlimab (RELA) + nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase 3 results from RELATIVITY-047 (CA224-047).
15:10 - 15:20	Presentation		Dr. Arnil Sirimanne	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.
15:20 - 15:30	Presentation		Dr. Jensow Sow	CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.
15:30 - 15:40	Presentation		Dr. Mohd Syahizul Nuhairy Mohd Sharial	Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma.
15:40 - 16:00 Exhibition Tour Break				
16:00 - 16:40 Session 12 - New Developments				
16:00 - 16:10	Presentation		Dr. Patricia Shamani Soosainathan	Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16 positive malignancies.
16:10 - 16:20	Presentation		Dr. Angel Kwan	Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs.
16:20 - 16:40	Session by Ipsen		Dr. Stephen L. Chan	Hepatocellular Carcinoma - Moving Forward with latest treatment options.
16:40 - 16:50 Quiz Session 2				
16:50 Onwards Award Declaration & Valedictory				

